Difference between revisions of "Pasdois 2007 J Mol Cell Cardiol"
(Created page with "{{Publication |title=Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adèle S, Garlid KD, Dos Santos P (2007) Sarcoplasmic ATP-sensitive potassium channel blocker...") |
|||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adèle S, Garlid KD, Dos Santos P (2007) Sarcoplasmic ATP-sensitive potassium channel blocker HMR1098 protects the ischemic heart: implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. J. Mol. Cell. Cardiol. 42: 631-642. | |title=Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adèle S, Garlid KD, Dos Santos P (2007) Sarcoplasmic ATP-sensitive potassium channel blocker HMR1098 protects the ischemic heart: implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. J. Mol. Cell. Cardiol. 42: 631-642. | ||
|authors=Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adele S, Garlid KD, Dos Santos P | |authors=Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adele S, Garlid KD, Dos Santos P | ||
|year=2007 | |year=2007 | ||
|journal= | |journal=J. Mol. Cell. Cardiol. | ||
|abstract=The aim of this study was to investigate the effects of HMR1098, a selective blocker of sarcolemmal ATP-sensitive potassium channel (sarcKATP), in Langendorff-perfused rat hearts submitted to ischemia and reperfusion. The recovery of heart hemodynamic and mitochondrial function, studied on skinned fibers, was analyzed after 30-min global ischemia followed by 20-min reperfusion. Infarct size was quantified on a regional ischemia model after 2-h reperfusion. We report that the perfusion of 10 μM HMR1098 before ischemia, delays the onset of ischemic contracture, improves recovery of cardiac function upon reperfusion, preserves the mitochondrial architecture, and finally decreases infarct size. This HMR1098-induced cardioprotection is prevented by 1 mM 2-mercaptopropionylglycine, an antioxidant, and by 100 nM nifedipine, an L-type calcium channel blocker. Concomitantly, it is shown that HMR1098 perfusion induces (i) a transient and specific inhibition of the respiratory chain complex I and, (ii) an increase in the averaged intracellular calcium concentration probed by the in situ measurement of indo-1 fluorescence. Finally, all the beneficial effects of HMR1098 were strongly inhibited by 5-hydroxydecanoate and abolished by glibenclamide, two mitoKATP blockers. This study demonstrates that the HMR1098-induced cardioprotection occurs indirectly through extracellular calcium influx, respiratory chain complex inhibition, reactive oxygen species production and mitoKATP opening. Taken together, these data suggest that a functional interaction between sarcKATP and mitoKATP exists in isolated rat heart ischemia model, which is mediated by extracellular calcium influx. | |abstract=The aim of this study was to investigate the effects of HMR1098, a selective blocker of sarcolemmal ATP-sensitive potassium channel (sarcKATP), in Langendorff-perfused rat hearts submitted to ischemia and reperfusion. The recovery of heart hemodynamic and mitochondrial function, studied on skinned fibers, was analyzed after 30-min global ischemia followed by 20-min reperfusion. Infarct size was quantified on a regional ischemia model after 2-h reperfusion. We report that the perfusion of 10 μM HMR1098 before ischemia, delays the onset of ischemic contracture, improves recovery of cardiac function upon reperfusion, preserves the mitochondrial architecture, and finally decreases infarct size. This HMR1098-induced cardioprotection is prevented by 1 mM 2-mercaptopropionylglycine, an antioxidant, and by 100 nM nifedipine, an L-type calcium channel blocker. Concomitantly, it is shown that HMR1098 perfusion induces (i) a transient and specific inhibition of the respiratory chain complex I and, (ii) an increase in the averaged intracellular calcium concentration probed by the in situ measurement of indo-1 fluorescence. Finally, all the beneficial effects of HMR1098 were strongly inhibited by 5-hydroxydecanoate and abolished by glibenclamide, two mitoKATP blockers. This study demonstrates that the HMR1098-induced cardioprotection occurs indirectly through extracellular calcium influx, respiratory chain complex inhibition, reactive oxygen species production and mitoKATP opening. Taken together, these data suggest that a functional interaction between sarcKATP and mitoKATP exists in isolated rat heart ischemia model, which is mediated by extracellular calcium influx. | ||
|keywords=Heart, schemia, Cardioprotection, Skinned fibers, Potassium channels | |keywords=Heart, schemia, Cardioprotection, Skinned fibers, Potassium channels | ||
| Line 16: | Line 16: | ||
|topics=Respiration; OXPHOS; ETS Capacity, Ion Homeostasis | |topics=Respiration; OXPHOS; ETS Capacity, Ion Homeostasis | ||
|instruments=Oxygraph-2k, Method | |instruments=Oxygraph-2k, Method | ||
}} | }} | ||
Revision as of 14:57, 20 October 2010
| Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adèle S, Garlid KD, Dos Santos P (2007) Sarcoplasmic ATP-sensitive potassium channel blocker HMR1098 protects the ischemic heart: implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. J. Mol. Cell. Cardiol. 42: 631-642. |
Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adele S, Garlid KD, Dos Santos P (2007) J. Mol. Cell. Cardiol.
Abstract: The aim of this study was to investigate the effects of HMR1098, a selective blocker of sarcolemmal ATP-sensitive potassium channel (sarcKATP), in Langendorff-perfused rat hearts submitted to ischemia and reperfusion. The recovery of heart hemodynamic and mitochondrial function, studied on skinned fibers, was analyzed after 30-min global ischemia followed by 20-min reperfusion. Infarct size was quantified on a regional ischemia model after 2-h reperfusion. We report that the perfusion of 10 μM HMR1098 before ischemia, delays the onset of ischemic contracture, improves recovery of cardiac function upon reperfusion, preserves the mitochondrial architecture, and finally decreases infarct size. This HMR1098-induced cardioprotection is prevented by 1 mM 2-mercaptopropionylglycine, an antioxidant, and by 100 nM nifedipine, an L-type calcium channel blocker. Concomitantly, it is shown that HMR1098 perfusion induces (i) a transient and specific inhibition of the respiratory chain complex I and, (ii) an increase in the averaged intracellular calcium concentration probed by the in situ measurement of indo-1 fluorescence. Finally, all the beneficial effects of HMR1098 were strongly inhibited by 5-hydroxydecanoate and abolished by glibenclamide, two mitoKATP blockers. This study demonstrates that the HMR1098-induced cardioprotection occurs indirectly through extracellular calcium influx, respiratory chain complex inhibition, reactive oxygen species production and mitoKATP opening. Taken together, these data suggest that a functional interaction between sarcKATP and mitoKATP exists in isolated rat heart ischemia model, which is mediated by extracellular calcium influx. • Keywords: Heart, schemia, Cardioprotection, Skinned fibers, Potassium channels
Labels:
Stress:Ischemia-Reperfusion; Preservation"Ischemia-Reperfusion; Preservation" is not in the list (Cell death, Cryopreservation, Ischemia-reperfusion, Permeability transition, Oxidative stress;RONS, Temperature, Hypoxia, Mitochondrial disease) of allowed values for the "Stress" property., RONS; Oxidative Stress"RONS; Oxidative Stress" is not in the list (Cell death, Cryopreservation, Ischemia-reperfusion, Permeability transition, Oxidative stress;RONS, Temperature, Hypoxia, Mitochondrial disease) of allowed values for the "Stress" property., Cancer; Apoptosis; Cytochrome c"Cancer; Apoptosis; Cytochrome c" is not in the list (Cell death, Cryopreservation, Ischemia-reperfusion, Permeability transition, Oxidative stress;RONS, Temperature, Hypoxia, Mitochondrial disease) of allowed values for the "Stress" property. Organism: Human Tissue;cell: Cardiac Muscle"Cardiac Muscle" is not in the list (Heart, Skeletal muscle, Nervous system, Liver, Kidney, Lung;gill, Islet cell;pancreas;thymus, Endothelial;epithelial;mesothelial cell, Blood cells, Fat, ...) of allowed values for the "Tissue and cell" property.
Enzyme: Complex I Regulation: Respiration; OXPHOS; ETS Capacity"Respiration; OXPHOS; ETS Capacity" is not in the list (Aerobic glycolysis, ADP, ATP, ATP production, AMP, Calcium, Coupling efficiency;uncoupling, Cyt c, Flux control, Inhibitor, ...) of allowed values for the "Respiration and regulation" property., Ion Homeostasis"Ion Homeostasis" is not in the list (Aerobic glycolysis, ADP, ATP, ATP production, AMP, Calcium, Coupling efficiency;uncoupling, Cyt c, Flux control, Inhibitor, ...) of allowed values for the "Respiration and regulation" property.
HRR: Oxygraph-2k, Method"Method" is not in the list (Oxygraph-2k, TIP2k, O2k-Fluorometer, pH, NO, TPP, Ca, O2k-Spectrophotometer, O2k-Manual, O2k-Protocol, ...) of allowed values for the "Instrument and method" property.
